Review





Similar Products

99
ATCC mouse crc cell lines ct26
Mouse Crc Cell Lines Ct26, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse crc cell lines ct26/product/ATCC
Average 99 stars, based on 1 article reviews
mouse crc cell lines ct26 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
ATCC mouse crc cell line ct26
Mouse Crc Cell Line Ct26, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse crc cell line ct26/product/ATCC
Average 99 stars, based on 1 article reviews
mouse crc cell line ct26 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
ATCC mouse crc cell line
Mouse Crc Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse crc cell line/product/ATCC
Average 99 stars, based on 1 article reviews
mouse crc cell line - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
ATCC mouse ct26 crc cell line
a Growth curves and weights of shVec/sh Mbtps1 MC38 tumors in female C57 mice (6-8 weeks old). b , c Growth curves of shVec/sh Mbtps1 <t>CT26</t> tumors in female BALB/c mice (6-8 weeks old) and E0771 tumors in C57 mice. d , e Growth curves of OEVec/OE Mbtps1 MC38 (d) and E0771 (e) tumors in C57 mice. f , g Growth curves of shVec/sh Mbtps1 MC38 tumors in female Rag1 -/- mice (5-6 weeks old) (f) and female BALB/c Nude mice (5-6 weeks old) ( g ). h Schematic of in vivo competition assay (scale bar: 100 μm). i , j Ratio changes of E0771 (i) and MC38 (j) cells cultured in vitro or tansplanted in C57 mice. k , l Growth curves (k), weights and tumor image (l, scale bar: 1 cm) of shVec/sh Mbtps1 MC38 tumors in anti-PD-1 (5 mg/kg, i.p.)-treated C57 mice. m Survival of shVec/sh Mbtps1 MC38 tumor-bearing mice treated with anti-PD-1 (5 mg/kg, i.p.). n Growth curves of E0771 tumors in anti-PD-1 (5 mg/kg, i.p.)-treated C57 mice. o , p Growth curves of KPC (o) and B16 (p) tumors in anti-PD-1 (10 mg/kg, i.p.)-treated C57 mice. q , r Growth curves (q) and weights (r) of MC38 tumors in C57 mice treated with half-dose anti-PD-1 (2.5 mg/kg). s Survival of E0771-bearing mice with half-dose anti-PD-1 (2.5 mg/kg). n = 6 mice per group in a – g and n – r ; n = 8 mice per group in i – l and s ; n = 10 mice per group in m . Data are presented as means ± SDs. Two-tailed unpaired Student’s t -test for a – g , i and j . one-way ANOVA with Sidak’s multiple comparisons test for k , l and n – r ; Kaplan-Meier analysis with the log-rank test for m and s . Source data are provided as a Source Data file.
Mouse Ct26 Crc Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse ct26 crc cell line/product/ATCC
Average 99 stars, based on 1 article reviews
mouse ct26 crc cell line - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


a Growth curves and weights of shVec/sh Mbtps1 MC38 tumors in female C57 mice (6-8 weeks old). b , c Growth curves of shVec/sh Mbtps1 CT26 tumors in female BALB/c mice (6-8 weeks old) and E0771 tumors in C57 mice. d , e Growth curves of OEVec/OE Mbtps1 MC38 (d) and E0771 (e) tumors in C57 mice. f , g Growth curves of shVec/sh Mbtps1 MC38 tumors in female Rag1 -/- mice (5-6 weeks old) (f) and female BALB/c Nude mice (5-6 weeks old) ( g ). h Schematic of in vivo competition assay (scale bar: 100 μm). i , j Ratio changes of E0771 (i) and MC38 (j) cells cultured in vitro or tansplanted in C57 mice. k , l Growth curves (k), weights and tumor image (l, scale bar: 1 cm) of shVec/sh Mbtps1 MC38 tumors in anti-PD-1 (5 mg/kg, i.p.)-treated C57 mice. m Survival of shVec/sh Mbtps1 MC38 tumor-bearing mice treated with anti-PD-1 (5 mg/kg, i.p.). n Growth curves of E0771 tumors in anti-PD-1 (5 mg/kg, i.p.)-treated C57 mice. o , p Growth curves of KPC (o) and B16 (p) tumors in anti-PD-1 (10 mg/kg, i.p.)-treated C57 mice. q , r Growth curves (q) and weights (r) of MC38 tumors in C57 mice treated with half-dose anti-PD-1 (2.5 mg/kg). s Survival of E0771-bearing mice with half-dose anti-PD-1 (2.5 mg/kg). n = 6 mice per group in a – g and n – r ; n = 8 mice per group in i – l and s ; n = 10 mice per group in m . Data are presented as means ± SDs. Two-tailed unpaired Student’s t -test for a – g , i and j . one-way ANOVA with Sidak’s multiple comparisons test for k , l and n – r ; Kaplan-Meier analysis with the log-rank test for m and s . Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy

doi: 10.1038/s41467-025-59193-4

Figure Lengend Snippet: a Growth curves and weights of shVec/sh Mbtps1 MC38 tumors in female C57 mice (6-8 weeks old). b , c Growth curves of shVec/sh Mbtps1 CT26 tumors in female BALB/c mice (6-8 weeks old) and E0771 tumors in C57 mice. d , e Growth curves of OEVec/OE Mbtps1 MC38 (d) and E0771 (e) tumors in C57 mice. f , g Growth curves of shVec/sh Mbtps1 MC38 tumors in female Rag1 -/- mice (5-6 weeks old) (f) and female BALB/c Nude mice (5-6 weeks old) ( g ). h Schematic of in vivo competition assay (scale bar: 100 μm). i , j Ratio changes of E0771 (i) and MC38 (j) cells cultured in vitro or tansplanted in C57 mice. k , l Growth curves (k), weights and tumor image (l, scale bar: 1 cm) of shVec/sh Mbtps1 MC38 tumors in anti-PD-1 (5 mg/kg, i.p.)-treated C57 mice. m Survival of shVec/sh Mbtps1 MC38 tumor-bearing mice treated with anti-PD-1 (5 mg/kg, i.p.). n Growth curves of E0771 tumors in anti-PD-1 (5 mg/kg, i.p.)-treated C57 mice. o , p Growth curves of KPC (o) and B16 (p) tumors in anti-PD-1 (10 mg/kg, i.p.)-treated C57 mice. q , r Growth curves (q) and weights (r) of MC38 tumors in C57 mice treated with half-dose anti-PD-1 (2.5 mg/kg). s Survival of E0771-bearing mice with half-dose anti-PD-1 (2.5 mg/kg). n = 6 mice per group in a – g and n – r ; n = 8 mice per group in i – l and s ; n = 10 mice per group in m . Data are presented as means ± SDs. Two-tailed unpaired Student’s t -test for a – g , i and j . one-way ANOVA with Sidak’s multiple comparisons test for k , l and n – r ; Kaplan-Meier analysis with the log-rank test for m and s . Source data are provided as a Source Data file.

Article Snippet: The human embryonic kidney (HEK) 293 T cell line, mouse CT26 CRC cell line, and E0771 mouse breast cancer cell line was purchased from the American Type Culture Collection (ATCC, Rockville, USA).

Techniques: In Vivo, Competitive Binding Assay, Cell Culture, In Vitro, Two Tailed Test

a Bar plots indicating the proportion of major cell lineages in each group. b Uniform manifold approximation and projection (UMAP) projection of 2340 lymphocytes from the shVec/sh Mbtps1 MC38 tumor groups, respectively. c Bar plots indicating the proportion of T cell lineages in each group. d , e The number and percentage of CD8 + T cells in shVec/sh Mbtps1 MC38 (d) or CT26 ( e ) tumors analyzed by flow cytometry. f , g The percentage of IFN-γ + CD8 + T cells in shVec/sh Mbtps1 MC38 (f) or CT26 (g) tumors analyzed by flow cytometry. h The percentage of Ki67 + CD8 + T cells in shVec/sh Mbtps1 CT26 tumors analyzed by flow cytometry. i The number or percentage of CD4 + T cells in shVec/sh Mbtps1 MC38 or CT26 tumors analyzed by flow cytometry. j The percentage of NK cells in shVec or sh Mbtps1 MC38 tumors analyzed by flow cytometry. k Flow cytometric analysis of the percentage of CD8 + T cells and IFN-γ + CD8 + T cells in female C57 mice (6-8 weeks old) with shVec/sh Mbtps1 MC38 tumors treated with αPD-1 or isotype control. l The percentage and number of CD8 + T cells in OEVec or OE Mbtps1 MC38 tumors analyzed by flow cytometry. m Statistical analysis of IHC stained CD8 + T cells in OEVec/OE Mbtps1 E0771 tumors. n , o Representative IHC staining images ( n ) and statistical analysis ( o ) of CD8 + T cells in MC38 tumors for the indicated groups. Scale bar, 50 μm. p Growth curves of shVec/sh Mbtps1 MC38 tumors in C57 mice treated with CD8 neutralizing antibody or isotype control. n = 5 mice per group in d , f , ( i , left) and j ; n = 6 mice in e , g , h , ( i , right), k – m , o and p . Data are presented as means ± SDs. Two-tailed unpaired Student’s t -test for d – j , l and m ; one-way ANOVA with Sidak’s multiple comparisons test for k , o and p . Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy

doi: 10.1038/s41467-025-59193-4

Figure Lengend Snippet: a Bar plots indicating the proportion of major cell lineages in each group. b Uniform manifold approximation and projection (UMAP) projection of 2340 lymphocytes from the shVec/sh Mbtps1 MC38 tumor groups, respectively. c Bar plots indicating the proportion of T cell lineages in each group. d , e The number and percentage of CD8 + T cells in shVec/sh Mbtps1 MC38 (d) or CT26 ( e ) tumors analyzed by flow cytometry. f , g The percentage of IFN-γ + CD8 + T cells in shVec/sh Mbtps1 MC38 (f) or CT26 (g) tumors analyzed by flow cytometry. h The percentage of Ki67 + CD8 + T cells in shVec/sh Mbtps1 CT26 tumors analyzed by flow cytometry. i The number or percentage of CD4 + T cells in shVec/sh Mbtps1 MC38 or CT26 tumors analyzed by flow cytometry. j The percentage of NK cells in shVec or sh Mbtps1 MC38 tumors analyzed by flow cytometry. k Flow cytometric analysis of the percentage of CD8 + T cells and IFN-γ + CD8 + T cells in female C57 mice (6-8 weeks old) with shVec/sh Mbtps1 MC38 tumors treated with αPD-1 or isotype control. l The percentage and number of CD8 + T cells in OEVec or OE Mbtps1 MC38 tumors analyzed by flow cytometry. m Statistical analysis of IHC stained CD8 + T cells in OEVec/OE Mbtps1 E0771 tumors. n , o Representative IHC staining images ( n ) and statistical analysis ( o ) of CD8 + T cells in MC38 tumors for the indicated groups. Scale bar, 50 μm. p Growth curves of shVec/sh Mbtps1 MC38 tumors in C57 mice treated with CD8 neutralizing antibody or isotype control. n = 5 mice per group in d , f , ( i , left) and j ; n = 6 mice in e , g , h , ( i , right), k – m , o and p . Data are presented as means ± SDs. Two-tailed unpaired Student’s t -test for d – j , l and m ; one-way ANOVA with Sidak’s multiple comparisons test for k , o and p . Source data are provided as a Source Data file.

Article Snippet: The human embryonic kidney (HEK) 293 T cell line, mouse CT26 CRC cell line, and E0771 mouse breast cancer cell line was purchased from the American Type Culture Collection (ATCC, Rockville, USA).

Techniques: Flow Cytometry, Control, Staining, Immunohistochemistry, Two Tailed Test

a , b Growth curves of MC38 tumors with indicated gene knockdown in female C57 mice (6-8 weeks old). c Growth curves of shVec, sh Mbtps1 and sh Srebf2 E0771 tumors in C57 mice subjected to CD or HCD feeding. d Growth curves of MC38 tumors from the indicated groups. e GSEA of chemokine pathway in sh Mbtps1 vs. shVec MC38 tumors. f qPCR analysis of Cxcl9 , Cxcl10 and Cxcl11 mRNA in MC38 cells. g – i ELISA detection of CXCL10 in the culture medium. j qPCR analysis of Cxcl10 mRNA in tumors from the indicated groups. k Number of CFSE-labeled CD8 + T cells migrated into the lower chamber when co-incubated with culture medium of MC38 cells. l qPCR analysis of Cxcr3 mRNA of tumors from the indicated groups. m Percentage of CXCR3 + cells in CD8 + T cells in CT26 tumors. n , o Representative images of immunofluorescence assay showing the staining of CXCR3 (red), CD8 (green) and nuclei (blue) ( n ) and quantification of CXCR3 + CD8 + T cells per high power field (o) in MC38 tumors. White arrows indicate CXCR3 + CD8 + T cells. Scale bar, 50 μm. p Percentages of IFN-γ positive and Ki67 positive cells in CXCR3 positive/negative CD8 + T cells. q Growth curves of MC38 tumors in anti-PD-1 treated C57 mice. r ELISA detection of CXCL10 in the tumor interstitial fluid of MC38 tumors. s Growth curves of shVec/sh Mbtps1 MC38 tumors in CXCR3 neutralizing antibody treated C57 mice. t , u Representative images ( t ) and quantification (u) of IHC stained CD8 + T cells in MC38 tumors. Yellow arrows indicate CD8-positive cells. Scale bar: 50 μm. n = 6 mice per group in a – d , m , o and q – u ; n = 5 mice per group in j and l ; n = 18 mice per group in p . n = 3 biologically independent samples per group, representative of three independent experiments with similar results in f – i and k . Data are presented as means ± SDs. Two-tailed unpaired Student’s t -test for a , b , f – h , k , m and n ; one-way ANOVA with Sidak’s multiple comparisons test for c , d , i , j , l , q - s and u ; two-tailed paired Student’s t -test for p . Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy

doi: 10.1038/s41467-025-59193-4

Figure Lengend Snippet: a , b Growth curves of MC38 tumors with indicated gene knockdown in female C57 mice (6-8 weeks old). c Growth curves of shVec, sh Mbtps1 and sh Srebf2 E0771 tumors in C57 mice subjected to CD or HCD feeding. d Growth curves of MC38 tumors from the indicated groups. e GSEA of chemokine pathway in sh Mbtps1 vs. shVec MC38 tumors. f qPCR analysis of Cxcl9 , Cxcl10 and Cxcl11 mRNA in MC38 cells. g – i ELISA detection of CXCL10 in the culture medium. j qPCR analysis of Cxcl10 mRNA in tumors from the indicated groups. k Number of CFSE-labeled CD8 + T cells migrated into the lower chamber when co-incubated with culture medium of MC38 cells. l qPCR analysis of Cxcr3 mRNA of tumors from the indicated groups. m Percentage of CXCR3 + cells in CD8 + T cells in CT26 tumors. n , o Representative images of immunofluorescence assay showing the staining of CXCR3 (red), CD8 (green) and nuclei (blue) ( n ) and quantification of CXCR3 + CD8 + T cells per high power field (o) in MC38 tumors. White arrows indicate CXCR3 + CD8 + T cells. Scale bar, 50 μm. p Percentages of IFN-γ positive and Ki67 positive cells in CXCR3 positive/negative CD8 + T cells. q Growth curves of MC38 tumors in anti-PD-1 treated C57 mice. r ELISA detection of CXCL10 in the tumor interstitial fluid of MC38 tumors. s Growth curves of shVec/sh Mbtps1 MC38 tumors in CXCR3 neutralizing antibody treated C57 mice. t , u Representative images ( t ) and quantification (u) of IHC stained CD8 + T cells in MC38 tumors. Yellow arrows indicate CD8-positive cells. Scale bar: 50 μm. n = 6 mice per group in a – d , m , o and q – u ; n = 5 mice per group in j and l ; n = 18 mice per group in p . n = 3 biologically independent samples per group, representative of three independent experiments with similar results in f – i and k . Data are presented as means ± SDs. Two-tailed unpaired Student’s t -test for a , b , f – h , k , m and n ; one-way ANOVA with Sidak’s multiple comparisons test for c , d , i , j , l , q - s and u ; two-tailed paired Student’s t -test for p . Source data are provided as a Source Data file.

Article Snippet: The human embryonic kidney (HEK) 293 T cell line, mouse CT26 CRC cell line, and E0771 mouse breast cancer cell line was purchased from the American Type Culture Collection (ATCC, Rockville, USA).

Techniques: Knockdown, Enzyme-linked Immunosorbent Assay, Labeling, Incubation, Immunofluorescence, Staining, Two Tailed Test